Two Labs Holdings, LLC

Two Labs Holdings, LLC specializes in providing comprehensive commercial solutions for pharmaceutical manufacturers, focusing on product launch and lifecycle management to enhance market access and compliance. Founded in 2003, Two Labs Holdings, LLC operates from Powell, US, offering services that include product launch and lifecycle management for pharmaceutical companies. Will Pih, the founder, has a history in the biopharma sector, and the company has completed three deals, with the most recent in November 2020 when it was acquired by Envision Pharma Group Limited from Excellere Partners. Two Labs offers a comprehensive suite of commercial solutions tailored to pharmaceutical manufacturers, focusing on product launch and lifecycle management.

Their core offerings include Medical Affairs and Communications services, providing publication support and strategic planning for small and emerging biopharma and biotech companies. Leveraging over a decade of experience, Two Labs has facilitated the launch of a significant percentage of products in the emerging biopharma market, creating integrated launch plans that resonate with healthcare providers, patients, payers, and investors. The company serves clients primarily in North America and Europe, enhancing compliance, streamlining operations, and ensuring effective market access strategies for various therapeutic products, including orphan drugs and specialty therapies. Two Labs generates revenue through service contracts and strategic partnerships with pharmaceutical manufacturers.

Their business model includes tailored consulting agreements, with clients engaging Two Labs for their expertise in navigating complex market dynamics. This typically involves fixed fees for specific services, such as strategic publication planning, and ongoing retainers for continued support throughout the product lifecycle. Their extensive portfolio includes successful collaborations, facilitating the launch of over 280 drugs, thereby solidifying their reputation in the industry. Following the acquisition by Envision Pharma Group Limited in November 2020, Two Labs aims to expand its service offerings and enter new markets in Europe and Asia by 2023.

The recent funding will be used to enhance their product development initiatives and support the introduction of new services designed for specialized therapeutic areas. The company plans to utilize its extensive experience in product launches to tap into emerging biopharma opportunities, further solidifying its position in the market.